209
Participants
Start Date
January 16, 2017
Primary Completion Date
October 3, 2019
Study Completion Date
May 8, 2023
Use of the test for treatment optimization
Intervention cohort, where the clinician will have information on the test results to support decision making on treatment optimization. The randomization process will be by blocks and weighted to the ADL/IFX ratio of use of these treatments in the usual clinical practice of the participating hospitals, to guarantee a homogeneous distribution of the treatments in the groups at the beginning/end of the follow-up.
Basurto University Hospital, Bilbao
PROGENIKA BIOPHARMA, A GRIFOLS Company
UNKNOWN
Hospital de Basurto
OTHER